CN101563342B - 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物 - Google Patents

用于治疗癌症的咪唑啉酮基氨基嘧啶化合物 Download PDF

Info

Publication number
CN101563342B
CN101563342B CN2007800472640A CN200780047264A CN101563342B CN 101563342 B CN101563342 B CN 101563342B CN 2007800472640 A CN2007800472640 A CN 2007800472640A CN 200780047264 A CN200780047264 A CN 200780047264A CN 101563342 B CN101563342 B CN 101563342B
Authority
CN
China
Prior art keywords
benzo
thiophen
ylamino
ethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800472640A
Other languages
English (en)
Chinese (zh)
Other versions
CN101563342A (zh
Inventor
李宏宇
H·B·布鲁克斯
J·Z·克里奇
J·R·亨里
M·K·斯拉特
王延
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101563342A publication Critical patent/CN101563342A/zh
Application granted granted Critical
Publication of CN101563342B publication Critical patent/CN101563342B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800472640A 2006-12-21 2007-12-11 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物 Expired - Fee Related CN101563342B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87130206P 2006-12-21 2006-12-21
US60/871,302 2006-12-21
PCT/US2007/087044 WO2008076704A1 (en) 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Publications (2)

Publication Number Publication Date
CN101563342A CN101563342A (zh) 2009-10-21
CN101563342B true CN101563342B (zh) 2012-09-05

Family

ID=39186811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800472640A Expired - Fee Related CN101563342B (zh) 2006-12-21 2007-12-11 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物

Country Status (14)

Country Link
US (1) US8101628B2 (enExample)
EP (1) EP2125793B1 (enExample)
JP (1) JP5166441B2 (enExample)
KR (1) KR101088291B1 (enExample)
CN (1) CN101563342B (enExample)
AT (1) ATE479680T1 (enExample)
AU (1) AU2007334039B2 (enExample)
BR (1) BRPI0721045A2 (enExample)
CA (1) CA2671738A1 (enExample)
DE (1) DE602007008952D1 (enExample)
EA (1) EA016177B1 (enExample)
ES (1) ES2349169T3 (enExample)
MX (1) MX2009006634A (enExample)
WO (1) WO2008076704A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016178B1 (ru) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Соединения имидазолидинониламинопиримидина
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) * 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005012283A1 (en) * 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
EA016178B1 (ru) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Соединения имидазолидинониламинопиримидина
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
WO2006066172A1 (en) * 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Also Published As

Publication number Publication date
CN101563342A (zh) 2009-10-21
US8101628B2 (en) 2012-01-24
US20100076001A1 (en) 2010-03-25
ATE479680T1 (de) 2010-09-15
ES2349169T3 (es) 2010-12-28
EA016177B1 (ru) 2012-02-28
EA200970615A1 (ru) 2009-10-30
JP5166441B2 (ja) 2013-03-21
KR101088291B1 (ko) 2011-11-30
AU2007334039A1 (en) 2008-06-26
WO2008076704A1 (en) 2008-06-26
AU2007334039B2 (en) 2012-02-16
DE602007008952D1 (de) 2010-10-14
BRPI0721045A2 (pt) 2014-07-29
JP2010513552A (ja) 2010-04-30
EP2125793B1 (en) 2010-09-01
MX2009006634A (es) 2009-06-30
EP2125793A1 (en) 2009-12-02
CA2671738A1 (en) 2008-06-26
KR20090086114A (ko) 2009-08-10

Similar Documents

Publication Publication Date Title
CN101679395B (zh) 三唑基氨基嘧啶化合物
CN101563342B (zh) 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物
KR101080594B1 (ko) 암의 치료를 위한 이미다졸리디노닐 아미노피리미딘 화합물
US8114872B2 (en) Triazolyl aminopyrimidine compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20121211